Inclusion Criteria:  Age over 18; Histologically or cytologically documented metastatic NSCLC, HER2 activation amplification or mutation stage IIIB-IV NSCLC patient; At least 1 measurable lesion according to RECIST 1.1; ECOG score 0 or 1; Life expectancy of at least 3 months;  Within one week before admission, blood routine examination was basically normal:  hemoglobin ≥90g/L or ≥5.6mmol/L; neutrophil count (ANC) ≥ 1.5 × 10 ^ 9 / L; platelet count (PLT) ≥ 100 × 10 ^ 9 / L; Liver and kidney function tests were basically normal within one week before enrollment; total bilirubin (TBIL) ≤ 1.5 × upper limit of normal value (ULN); alanine aminotransferase (ALT / AST) ≤ 2.5 × ULN (liver metastasis patients ≤ 5xuln); serum creatinine ≤ 1.5 × ULN; Partially activated thrombin time(APTT)≤ 1.5 × ULN; For fertile women had negative blood pregnancy tests 7 days before screening; willing to participate and sign the informed consent in person.  Exclusion Criteria:  Patients who have received anti-HER2 monoclonal antibody therapy; Have received chemotherapy, biotherapy, targeted therapy, immunotherapy and other anti-tumor therapies within 4 weeks prior to the first use of the study drug including: oral small molecule targeted drugs within 2 weeks prior to the first use of the study drug or within 5 half-lives of known drugs (depending on the time);Radiotherapy was performed within 2 weeks prior to the first administration of the study drug; Have received other clinical study drugs within 4 weeks prior to the first study drug administration; Patients who underwent major surgery within 4 weeks prior to the first dosing of the study drug(except needle biopsy or significant trauma); Those who have been known to have allergic history to the drug components of this regimen; Study drugs that had used a CYP3A4 inhibitor, inducer, or a narrow therapeutic window with a CYP3A4-sensitive substrate ,P-ep strong inducer and inhibitor within 14 days before first administration; The adverse reactions of previous antitumor therapy have not recovered to CTCAE 5.0 grade 1(Hair loss and other toxicities were excluded for which the researchers judged no safety risk); Patients with central nervous system metastasis and clinical symptoms; History of immunodeficiency, including positive HIV test, or suffering from other acquired, congenital immunodeficiency diseases, or history of organ transplantation; Active hepatitis B (HBV virus titer 1000 copies /ml or 200IU/ml);Hepatitis C virus, syphilis infection; Severe heart disease or discomfort, including, but not limited to, the following: complete left bundle branch block or degree atrioventricular block, history of myocardial infarction, angioplasty, coronary artery bridging, patients with prolonged QT/QTc interval at baseline (QTcF men >450 ms, women >480ms), significant ventricular arrhythmias (such as ventricular tachycardia), history of heart failure or systolic dysfunction (LVEF < 50%), cardiac failure, New York College of Cardiology (NYHA) grade II or higher, uncontrolled hypertension (systolic blood pressure > 180 mmHg ), history or current history of cardiomyopathy that the investigator judged to have an impact on the study; Inability to swallow medications orally, or that the investigator determines severely affect gastrointestinal absorption; Other malignant tumors in the past 5 years, excluding cured cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma or in situ cervical cancer and/or breast cancer; Any history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonia requiring steroid treatment, or evidence of clinically active interstitial lung disease; Patients with a history of other serious systemic diseases who were judged by the investigator to be unsuitable for clinical trials; Alcohol or drug dependence; Have a clear history of neurological or mental disorders, including epilepsy or dementia; Pregnant and/or breastfeeding; Any other reason the investigator considers the patient is not suitable to participate in the study.